Therapeutic Advances In Hematology

SCI SCIE

国际简称：THER ADV HEMATOL 参考译名：血液学的治疗进展

主要研究方向：HEMATOLOGY 非预警期刊审稿周期：7 Weeks

《血液学的治疗进展》(Therapeutic Advances In Hematology)是一本由SAGE PUBLICATIONS LTD出版的以HEMATOLOGY为研究特色的国际期刊，发表该领域相关的原创研究文章、评论文章和综述文章，及时报道该领域相关理论、实践和应用学科的最新发现，旨在促进该学科领域科学信息的快速交流。该期刊是一本开放期刊，近三年没有被列入预警名单。该期刊享有很高的科学声誉，影响因子不断增加，发行量也同样高。

2区中科院分区
Q2 JCR分区
58 年发文量
2.8 IF影响因子
开放是否OA
2010 创刊年份
1 issue/year 出版周期
English 出版语言

Therapeutic Advances in Hematology delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of hematology. The journal has a strong clinical and pharmacological focus and is aimed at clinicians and researchers in hematology, providing a forum in print and online for publishing the highest quality articles in this area.

[ 查看全部 ]

投稿咨询加急咨询

Therapeutic Advances In Hematology期刊信息

ISSN：2040-6207
出版语言：English
是否OA：开放
E-ISSN：2040-6215
出版地区：United States
是否预警：否
出版商：SAGE PUBLICATIONS LTD
出版周期：1 issue/year
创刊时间：2010
开源占比：0.8889
Gold OA文章占比：100.00%
OA被引用占比：0.6843...
出版国人文章占比：0.06
出版撤稿占比：
研究类文章占比：84.48%

Therapeutic Advances In Hematology CiteScore评价数据（2026年6月最新版）

CiteScore

SJR

SNIP

CiteScore 指数

5.3

1.018

0.826

学科类别	分区	排名	百分位
大类：Medicine 小类：Hematology	Q1	36 / 151	76%

名词解释：CiteScore 是衡量期刊所发表文献的平均受引用次数，是在 Scopus 中衡量期刊影响力的另一个指标。当年CiteScore 的计算依据是期刊最近4年（含计算年度）的被引次数除以该期刊近四年发表的文献数。例如，2022年的 CiteScore 计算方法为：2022年的 CiteScore =2019-2022年收到的对2019-2022年发表的文件的引用数量÷2019-2022年发布的文献数量注：文献类型包括：文章、评论、会议论文、书籍章节和数据论文。

Therapeutic Advances In Hematology中科院评价数据

《新锐期刊分区表》（2026年3月发布）

Top期刊	综述期刊	大类学科		小类学科
否	否	医学	2区	HEMATOLOGY 血液学	2区

Therapeutic Advances In Hematology JCR评价数据

2025-2026年最新版

按JCI指标学科分区	收录子集	分区	排名	百分位
学科：HEMATOLOGY	SCIE	Q2	42 / 103	59.7
学科：HEMATOLOGY	SCIE	Q2	42 / 103	59.71

Therapeutic Advances In Hematology历年数据统计

影响因子

中科院分区

Therapeutic Advances In Hematology中国学者发文选摘

1、A phase I/II study of gilteritinib in combination with chemotherapy in newly diagnosed patients with AML in Asia: final analysi
Author: Sawa, Masashi; Miyamoto, Toshihiro; Kim, Hee-Je; Hiramatsu, Yasushi; Cheong, June-Won; Ikezoe, Takayuki; Naoe, Tomoki; Akashi, Koichi; Morita, Satoshi; Kosako, Masanori; Shimura, Masaki; Terada, Wataru; Kadokura, Takeshi; Hill, Jason; Miyawaki, Shuichi; Gill, Stanley C.; Heinloth, Alexandra; Hasabou, Nahla

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261419953
2、Assessment of flonoltinib maleate versus ruxolitinib phosphate in intermediate- to high-risk myelofibrosis (FMF-02): study protocol for a multicenter, randomized, open-label phase IIB tria
Author: Yang, Linyu; Tan, Ke; Liang, Rui; Zhang, Wei; Wang, Yiqun; Chen, Lijuan

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261424845
3、The impact of clinical manifestations on the prognosis of diffuse large B-cell lymphom
Author: Wang, Siqian; Xu, Xi; Ma, Yongyong; Qian, Shanhu; Tang, Liyuan; Sun, Lan; Shen, Zhijian; Ye, Haige; Qian, Honglan; Jiang, Songfu; Zhou, Shujuan

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207251410405
4、Early-onset de novo donor-specific anti-HLA antibodies may contribute to poor graft function following haploidentical transplantation for myelodysplastic syndrome: a rare case presentatio
Author: Huang, Xianbo; Wu, Xianhui; Wang, Shasha; Xu, Yu; Mei, Chen; Du, Fengwei; Ren, Yanling; Jin, Jie; Tong, Hongyan; Qian, Jiejing

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417496
5、Real-world clinical outcomes of autologous stem cell transplantation in Chinese patients with newly diagnosed multiple myeloma: a systematic literature revie
Author: You, Jiawen; Zhang, Yuanyuan; Meng, Yuan; Zhao, Yiming; Huang, Huiqing; Chen, Wendong; Meng, Jianbo

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417132
6、Endothelial dysfunction and cardiac damage indicators in patients with β-thalassemia major under iron-chelation therap
Author: Al-Sanabra, Ola M.; Abbas, Manal A.; Haza, Wafa J.; Hazaa, Abeer A

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261417140
7、Comparing two different doses of anti-thymocyte globulin in allogeneic hematopoietic stem cell transplantation for transfusion-dependent thalassemia: an open-label, randomized clinical tria
Author: Huang, Qiulin; Liu, Rongrong; Zheng, Baoshi; Liu, Lianjin; Xiao, Hongwen; Wu, Meiqing; Shi, Lingling; Yang, Gaohui; Wei, Zhenbin; Zhou, Qi; Chen, Yinghua; Liu, Yanye; Fan, Jing; Zhou, Xuemei; Li, Ruolin; Zeng, Zhiyu; Zhang, Zhongming; Lai, Yongrong

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261416816
8、Recombinant von Willebrand factor for von Willebrand disease: mechanism of action and clinical applicatio
Author: Hua, Zhengjie; Miao, Wenjuan; Zhang, Ping; Yang, Renchi

Journal: THERAPEUTIC ADVANCES IN HEMATOLOGY. 2026; Vol. 17, Issue , pp. -. DOI: 10.1177/20406207261419941